Table 1 Characteristics of the patient group studied
From: Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome
| Ā | N | % | Mean (SD) | Median | Range |
|---|---|---|---|---|---|
Age | 118 | Ā | 52.9 (10.3) | 53.2 | 32.3ā72.5 |
Males | 76 | 68.5 | Ā | Ā | Ā |
Females | 35 | 31.5 | Ā | Ā | Ā |
Duration of treatment (years) | 110 | Ā | 0.5 (0.4) | 0.3 | 0.02ā2.1 |
Diabetes | 31 | 28.2 | Ā | Ā | Ā |
On concurrent statin treatment | 60 | 52.6 | Ā | Ā | Ā |
Never smoked | 15 | 13.8 | Ā | Ā | Ā |
Ex-smokers | 77 | 70.6 | Ā | Ā | Ā |
Current smokers | 17 | 15.6 | Ā | Ā | Ā |
Alcohol (units/week) | Ā | Ā | Ā | Ā | Ā |
0 | 16 | 16.8 | Ā | Ā | Ā |
1ā28 | 55 | 57.9 | Ā | Ā | Ā |
>28 | 24 | 25.8 | Ā | Ā | Ā |
Pre-fibrate treatment | Ā | Ā | Ā | Ā | Ā |
TC (mmol/l) | 117 | Ā | 6.8 (2.6) | 6.1 | 3.4ā20.2 |
TG (mmol/l) | 118 | Ā | 7.3 (7.8) | 5.1 | 1.4ā58.1 |
HDL-C (mmol/l) | 98 | Ā | 1.1 (0.2) | 1.1 | 0.7ā1.9 |
Creatinine (Ī¼mol/l) | 109 | Ā | 84.1 (16.8) | 84 | 33ā127 |
GGT (IU/l) | 118 | Ā | 79.2 (59.8) | 57.5 | 13ā274 |
ALT (IU/l) | 116 | Ā | 43.1 (33.5) | 33.5 | 9ā249 |
ALP (IU/l) | 118 | Ā | 81.2 (24.2) | 77.5 | 34ā177 |
Post-fibrate treatment | Ā | Ā | Ā | Ā | Ā |
TC (mmol/l) | 118 | Ā | 5.8 (1.4) | 5.6 | 3ā11.2 |
TG (mmol/l) | 118 | Ā | 3.7 (3.8) | 2.7 | 0.8ā34.4 |
HDL-C (mmol/l) | 115 | Ā | 1.2 (0.3) | 1.1 | 0.6ā2.5 |
Creatinine (Ī¼mol/l) | 115 | Ā | 95.1 (20.0) | 92 | 59ā143 |
GGT (IU/l) | 116 | Ā | 57.1 (43.6) | 42 | 13ā307 |
ALT (IU/l) | 116 | Ā | 37.5 (24.5) | 30 | 12ā154 |
ALP (IU/l) | 118 | Ā | 62.0 (19.9) | 59 | 23ā147 |